| Patient . | Age . | Sex . | IHCa . | PVB19 . | PMN . | NETs . | Medication . | Symptoms . | LVEF at diagnosis (%) . | Follow up (yr) . | LVEF at follow up . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47 | f | + | + | + | − | BB, ACEI, diuretics | Heart failure | 10 | 3 | 32% |
| 2 | 29 | f | + | + | + | − | BB, ACEI, MRA, diuretics | Heart failure | 28 | 11 | 41% |
| 3 | 48 | m | + | + | + | − | BB, ACEI, MRA, diuretics | Heart failure | 29 | None | — |
| 4 | 36 | m | + | + | + | − | BB, ACEI, corticosteroids | Cardiac arrest | 30 | <1 | Normalized |
| 5 | 44 | m | + | + | + | + | BB, ACEI, diuretics | Heart failure and angina pectoris | 37 | None | — |
| 6 | 30 | f | + | + | + | + | BB, ACEI, diuretics | Heart failure | 45 | 10 | Normalized |
| 7 | 24 | f | + | − | + | + | ACEI | LV thrombus | Normal | None | — |
| 8 | 55 | m | + | − | + | + | BB, ACEI | Heart failure | 30 | 10 | Normalized |
| 9 | 75 | f | + | − | + | + | BB, MRA, diuretics | Angina pectoris | 30 | None | — |
| 10 | 46 | m | + | − | + | + | BB, ACEI, MRA, diuretics | Heart failure | 27 | <1 | 40% |
| 11 | 64 | m | + | − | + | + | BB, ACEI, diuretics | Heart failure | 25 | <1 | 27% |
| 12 | 56 | m | + | − | + | + | BB, ACEI, MRA, diuretics | Heart failure | 18 | <1 | 45% |
| 13 | Unknown | m | + | − | + | + | Unknown | Unknown | Unknown | Unknown | Unknown |
| 14 | 37 | m | + | − | + | + | BB, ACEI, MRA, diuretics | Heart failure | 23 | None | — |
| Patient . | Age . | Sex . | IHCa . | PVB19 . | PMN . | NETs . | Medication . | Symptoms . | LVEF at diagnosis (%) . | Follow up (yr) . | LVEF at follow up . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 47 | f | + | + | + | − | BB, ACEI, diuretics | Heart failure | 10 | 3 | 32% |
| 2 | 29 | f | + | + | + | − | BB, ACEI, MRA, diuretics | Heart failure | 28 | 11 | 41% |
| 3 | 48 | m | + | + | + | − | BB, ACEI, MRA, diuretics | Heart failure | 29 | None | — |
| 4 | 36 | m | + | + | + | − | BB, ACEI, corticosteroids | Cardiac arrest | 30 | <1 | Normalized |
| 5 | 44 | m | + | + | + | + | BB, ACEI, diuretics | Heart failure and angina pectoris | 37 | None | — |
| 6 | 30 | f | + | + | + | + | BB, ACEI, diuretics | Heart failure | 45 | 10 | Normalized |
| 7 | 24 | f | + | − | + | + | ACEI | LV thrombus | Normal | None | — |
| 8 | 55 | m | + | − | + | + | BB, ACEI | Heart failure | 30 | 10 | Normalized |
| 9 | 75 | f | + | − | + | + | BB, MRA, diuretics | Angina pectoris | 30 | None | — |
| 10 | 46 | m | + | − | + | + | BB, ACEI, MRA, diuretics | Heart failure | 27 | <1 | 40% |
| 11 | 64 | m | + | − | + | + | BB, ACEI, diuretics | Heart failure | 25 | <1 | 27% |
| 12 | 56 | m | + | − | + | + | BB, ACEI, MRA, diuretics | Heart failure | 18 | <1 | 45% |
| 13 | Unknown | m | + | − | + | + | Unknown | Unknown | Unknown | Unknown | Unknown |
| 14 | 37 | m | + | − | + | + | BB, ACEI, MRA, diuretics | Heart failure | 23 | None | — |
ACEI, angiotensin-converting enzyme inhibitor; BB, beta blocker; f, female; LV, left ventricle; LVEF, left ventricular ejection fraction; m, male; MRA, mineralocorticoid receptor antagonist.
≥ 14 leukocytes/mm2 and HLA-DR overexpression.